Literature DB >> 31712972

[Basics of the pharmacology of biopharmaceuticals].

Johannes Wohlrab1,2.   

Abstract

Biopharmaceuticals are pharmaceutical drug products or preparations of pharmaceutical drugs that are of biological origin or are manufactured from biological material. The spectrum of biological drugs is extensive and includes substances isolated from biological material, recombinant RNA molecules, proteins as well as full antibodies, antibody fragments or antibody-drug conjugates. The special features of the molecular properties and functions of biopharmaceuticals require a highly complex, variable structure. Due to the specificity of intended pharmacodynamic effects on a complex biological regulatory system, particularities regarding undesired effects, pharmacokinetics, and safety have to be considered both regulatory and clinical.

Keywords:  Biological products; Biologics; Fusion proteins; Peptides; Therapeutic antibodies

Mesh:

Substances:

Year:  2019        PMID: 31712972     DOI: 10.1007/s00105-019-04502-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  33 in total

1.  Side effects of the biologics.

Authors:  Warren R Heymann
Journal:  J Am Acad Dermatol       Date:  2005-10       Impact factor: 11.527

2.  Quality of biotechnological products: stability testing of biotechnological/biological products. Annex to the ICH Harmonised Tripartite Guideline for the Stability Testing of New Drug Substances and Products.

Authors: 
Journal:  Dev Biol Stand       Date:  1998

3.  Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.

Authors: 
Journal:  Dev Biol Stand       Date:  1998

Review 4.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 5.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 6.  Pharmacokinetic characteristics of therapeutic antibodies.

Authors:  Johannes Wohlrab
Journal:  J Dtsch Dermatol Ges       Date:  2015-06       Impact factor: 5.584

Review 7.  Biologics for chronic inflammatory skin diseases: an update for the clinician.

Authors:  Yiqiu Yao; Astrid-Helene Ravn Jørgensen; Simon Francis Thomsen
Journal:  J Dermatolog Treat       Date:  2019-03-25       Impact factor: 3.359

8.  Trifunctional metasurfaces: concept and characterizations.

Authors:  Weikang Pan; Tong Cai; Shiwei Tang; Lei Zhou; Jianfeng Dong
Journal:  Opt Express       Date:  2018-06-25       Impact factor: 3.894

9.  Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.

Authors:  Joop van Gerven; Milton Bonelli
Journal:  Br J Clin Pharmacol       Date:  2018-05-30       Impact factor: 4.335

10.  Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris.

Authors:  Stefan Ryckaert; Els Pardon; Jan Steyaert; Nico Callewaert
Journal:  J Biotechnol       Date:  2009-10-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.